New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
- PMID: 27797968
- DOI: 10.1158/1078-0432.CCR-16-0184
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Abstract
Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in the clinical potential of immunotherapy for the treatment of multiple myeloma. Clinical progression of myeloma is known to be associated with progressive immune dysregulation and loss of immune surveillance that contribute to disease progression in association with progressive genetic complexity, rendering signaling-based treatments less effective. A variety of strategies to reverse the multiple myeloma-induced immunosuppression has been developed either in the form of immunomodulatory drugs, checkpoint inhibitors, mAbs, engineered T cells, and vaccines. They have shown encouraging results in patients with relapsed refractory multiple myeloma and hold great promise in further improving patient outcomes in multiple myeloma. This review will summarize the major approaches in multiple myeloma immunotherapies and discuss the mechanisms of action and clinical activity of these strategies. Clin Cancer Res; 22(24); 5959-65. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Immune Therapies in Multiple Myeloma.Clin Cancer Res. 2016 Nov 15;22(22):5453-5460. doi: 10.1158/1078-0432.CCR-16-0868. Clin Cancer Res. 2016. PMID: 28151713 Review.
-
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6. Pharmacotherapy. 2017. PMID: 27870103 Review.
-
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834. Curr Cancer Drug Targets. 2017. PMID: 28201977 Review.
-
Immunopathogenesis and immunotherapy of multiple myeloma.Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24. Int J Hematol. 2018. PMID: 29368256 Review.
-
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Epub 2016 Feb 17. Immunotherapy. 2016. PMID: 26888183 Review.
Cited by
-
Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment.Front Immunol. 2022 Jul 7;13:909880. doi: 10.3389/fimmu.2022.909880. eCollection 2022. Front Immunol. 2022. PMID: 35874665 Free PMC article.
-
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.Blood Cancer J. 2024 Nov 28;14(1):208. doi: 10.1038/s41408-024-01185-6. Blood Cancer J. 2024. PMID: 39609411 Free PMC article.
-
Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance.J Clin Med. 2022 Nov 1;11(21):6491. doi: 10.3390/jcm11216491. J Clin Med. 2022. PMID: 36362718 Free PMC article. Review.
-
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018. Front Immunol. 2018. PMID: 30455698 Free PMC article. Review.
-
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.Cancer Sci. 2022 Dec;113(12):4267-4276. doi: 10.1111/cas.15556. Epub 2022 Oct 7. Cancer Sci. 2022. PMID: 36052883 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical